[ad_1]
Mumbai: Clinical research organization (CRO) Parexel has announced the appointment of Jim Anthony as Chief Commercial Officer (CCO) and President, Parexel Biotech.
The expanded role is aimed at strengthening the company’s customer engagement and supporting its growth strategy.
It is indicated that Anthony has led Parexel Biotech since 2019 and most recently served as President and Global Head, Parexel Biotech.
In his new role, he will oversee customer strategy and relationships across both biotech and pharmaceutical sectors worldwide. He will also oversee clinical development capabilities from Phase I to IV.
As part of long-term succession planning, Conal Burgess, President and Global Head, Enterprise Partnerships, will transition from his role on December 31, 2025, following a 30-year career with Parexel.
According to the company, Anthony brings more than 25 years of experience in pharmaceutical development and the CRO industry. He has held leadership positions of increasing responsibility, including Corporate Vice President, Enterprise Account Leader, where he managed two of Parexel’s largest pharmaceutical customers, and Executive Vice President and Global Head, Parexel Biotech. He was appointed President and Global Head, Parexel Biotech in 2023.
“I’m honored to serve in this expanded leadership role at such a pivotal time for our customers and our company,” said Anthony.
[ad_2]
Source link
